In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is
the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 …

PURPOSE To provide evidence-based recommendations updating the 2017 ASCO
guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) …

PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …

Lung adenocarcinoma (LUAD) is one of the most common malignancies worldwide.
Combination chemotherapy with cisplatin (CDDP) plus pemetrexed (PEM) remains the …

Purpose The Iressa Mutation-Positive Multicentre Treatment Beyond ProgRESsion Study
(IMPRESS) compared the continuation of gefitinib plus chemotherapy with placebo plus …

After the discovery of activating mutations in EGFR, EGFR tyrosine kinase inhibitors (TKIs)
have been introduced into the first-line treatment of non-small-cell lung cancer (NSCLC). A …

Lung cancer still contributes to nearly one‐quarter cancer‐related deaths in the past
decades, despite the rapid development of targeted therapy and immunotherapy in non …

Objective To compare the efficacy and safety of first line treatments for patients with
advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer …

The discovery of epidermal growth factor receptor (EGFR) activating mutations in non-small
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …